Literature DB >> 30225390

A systematic review and meta-analysis of treatment for hepatorenal syndrome with traditional Chinese medicine.

Tingxue Song1,2, Xiaozhong Guo1, Lichun Shao2, Mingyu Sun3, Fernando Gomes Romeiro4, Dan Han1, Wenchun Bao1, Xingshun Qi1.   

Abstract

BACKGROUND: Hepatorenal syndrome (HRS) is a life-threatening complication of end-stage liver diseases. It has been reported that traditional Chinese medicine (TCM) may improve liver function, delay disease progression, alleviate symptoms, and improve quality of life in HRS patients. The study aims to systematically review the efficacy of TCM for the treatment of HRS.
METHODS: Publications were searched electronically from China National Knowledge Infrastructure (CNKI), Wanfang, VIP, PubMed, and EMBASE databases. Odds ratio (OR) and standardized mean difference (SMD) with 95% confidence interval (CI) were calculated. Heterogeneity was assessed. The Cochrane Collaboration's tool was used to assess the risk of bias.
RESULTS: Fourteen randomized controlled trials involving 788 patients with HRS were included. Random generation sequence was reported in only two studies. Blinding was not used in any study. Compared to conventional treatment without TCM, TCM led to a significant survival benefit during hospitalization (OR: 0.18; 95% CI: 0.08-0.39; P<0.0001), a significantly higher complete response (OR: 3.20; 95% CI: 2.06-4.97; P<0.00001), and a significantly lower no response (OR: 0.20; 95% CI: 0.14-0.30; P<0.00001). Partial response was not significantly different between the two groups (OR: 1.39; 95% CI: 0.90-2.15; P=0.14). Regardless of TCM, blood urea nitrogen and abdominal circumference were significantly decreased, and urine volume was significantly increased after treatment. Compared to conventional treatment without TCM, TCM led to a significantly lower serum creatinine, blood urea nitrogen, bilirubin, plasma ammonia, and abdominal circumference and significantly higher urine volume after treatment. There was significant heterogeneity.
CONCLUSIONS: TCM might have a better survival and a higher complete response in patients with HRS. However, the quality of published studies was unsatisfactory.

Entities:  

Keywords:  Traditional Chinese medicine (TCM); hepatorenal syndrome (HRS); liver function; renal function; response; terlipressin

Year:  2018        PMID: 30225390      PMCID: PMC6131225          DOI: 10.21037/tgh.2018.08.02

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  15 in total

Review 1.  [Progress in study on mechanisms of rhubarb in treating chronic renal failure].

Authors:  Wei Zhu; Xue-mei Wang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2005-05

2.  Therapy with vasoconstrictor drugs in cirrhosis: The time has arrived.

Authors:  Pere Ginès; Mónica Guevara
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

Review 3.  Renal failure in cirrhosis.

Authors:  Pere Ginès; Robert W Schrier
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

4.  Salvia miltiorrhiza compounds protect the liver from acute injury by regulation of p38 and NFκB signaling in Kupffer cells.

Authors:  Shuqiang Yue; Bin Hu; Zhipeng Wang; Zhenggang Yue; Fang Wang; Yuan Zhao; Zhifu Yang; Min Shen
Journal:  Pharm Biol       Date:  2014-07-15       Impact factor: 3.503

5.  Gut flora may offer new therapeutic targets for the traditional Chinese medicine enteric dialysis.

Authors:  Zhan-Jun Shu; Ying Cao; Upur Halmurat
Journal:  Expert Opin Ther Targets       Date:  2011-09-09       Impact factor: 6.902

Review 6.  Comparative efficacy of vasoconstrictor therapies for type 1 hepatorenal syndrome: a network meta-analysis.

Authors:  Ji-Na Zheng; Yi-Jing Han; Tian-Tian Zou; Yu-Jie Zhou; Dan-Qin Sun; Jian-Hong Zhong; Martin Braddock; Ming-Hua Zheng
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2017-07-27       Impact factor: 3.869

7.  Hepatorenal syndrome type 1 and bacterial infection: a catastrophic association in patients with cirrhosis.

Authors:  Francesco Salerno; Valentina Monti
Journal:  Hepatology       Date:  2014-02-28       Impact factor: 17.425

Review 8.  Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders.

Authors:  Rolf Teschke; Albrecht Wolff; Christian Frenzel; Axel Eickhoff; Johannes Schulze
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

9.  Pharmacological Therapies for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Arjun Nanda; Rewanth Reddy; Humaira Safraz; Habeeb Salameh; Ashwani K Singal
Journal:  J Clin Gastroenterol       Date:  2018-04       Impact factor: 3.062

10.  Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis.

Authors:  Antonio Paulo Nassar Junior; Alberto Queiroz Farias; Luiz Augusto Carneiro D' Albuquerque; Flair José Carrilho; Luiz Marcelo Sá Malbouisson
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

View more
  1 in total

Review 1.  Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians.

Authors:  Andrea Gallo; Cristina Dedionigi; Chiara Civitelli; Anna Panzeri; Chiara Corradi; Alessandro Squizzato
Journal:  J Transl Int Med       Date:  2020-12-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.